The U.S. Food and Drug Administration (FDA) has turned down an application for a combo allergy drug. The medication would have combined the allergy medication Claritin with the asthma, allergy drug Singulair. Drugmakers Merck and Schering-Plough issued statements that they were still evaluating the FDA's response. Experts stress that both medications will continue to be offered separately.
Read moreThere are tons of allergy medicines available, both over the counter and by prescription. So, how can you know which one is best? The... Read more »
Did you see the reports last week that Singulair was going to be investigated by the Food and Drug Administration for reports of a "casual... Read more »
My e-mail is buzzing. "Have you seen the news about Singulair? Are you worried?" The short answer is, "No, I'm not concerned at all." ... Read more »
The Food and Drug Administration is scheduled to review a new allergy medication for market approval. The med is a combination of the asthma drug... Read more »
What is the concern about Singulair (montelukast)?Singulair is a major drug in asthma treatment – it is important to review recent developments and... Read more »
Source: First DataBank
Generic Name: MONTELUKAST GRANULES - ORAL Pronounced: (mon-teh-LEW-kast) Side Effects Unusual weakness, stomach upset, diarrhea, dizziness,... Read more »
A mother-to-be wants to know if it is safe to treat asthma symptoms with Flovent, Claritin, and albuterol while breast-feeding. International... Read more »
Researchers from the American Lung Association (ALA) say they've found no link between the asthma drug Singulair and an increased risk of suicide and... Read more »